The Imspex Group’s BreathSpec® technology is well-placed to play a leading role in combatting antimicrobial resistance by helping healthcare practitioners to differentiate between bacterial and viral causes of respiratory infection. This would better allow the right antibiotic to be prescribed to the right patient at the right time and in the right dose , thereby helping to minimise unnecessary prescription of antibiotics.
These findings arose from a successful bid in 2019 for €1.5 million of Horizon 2020 funding. In the consortium, Imspex Diagnostics Ltd, together with consortium clinical trial partners in Germany and Ireland, as well as the University of Warwick and RedKnight Consultancy Ltd, carried out studies that showed BreathSpec®’s ability to differentiate between bacterial and viral causes of respiratory infection.
These findings, together with those from the current COVID-19-focus of the Imspex Group’s work, hold promise for being able to better detect infectious respiratory disease conditions and to slow the effect of antimicrobial resistance. Read more here and here.